GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, announced that its executive medical and scientific team will deliver presentations at the World Vaccine Congress Europe 2025, scheduled for October 13–16, 2025, at the RAI Amsterdam Convention Centre in Amsterdam, Netherlands.
Mark J. Newman, PhD, Chief Scientific Officer, will participate in the Special Populations Workshop on October 13 at 14:00 CEST, addressing vaccine development for immunocompromised individuals. His presentation, titled “Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory,” will focus on strategies to enhance immune responses in vulnerable groups.
Kelly T. McKee, Jr., MD, MPH, Chief Medical Officer, will present a scientific poster titled “Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies.” The poster will be on display in the Poster Zone from October 14–16.
GEO-CM04S1 is a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, evaluating its use as a primary vaccine for immunocompromised patients, a booster in chronic lymphocytic leukemia (CLL) patients, and a durable booster in healthy individuals previously vaccinated with mRNA vaccines. The data to be presented underscore the vaccine’s safety profile in a target population with high unmet medical need.
“World Vaccine Congress Europe is one of the most important international gatherings in vaccine research, development and policy,” said David Dodd, GeoVax President & CEO. “We look forward to highlighting the progress of our multi-antigen GEO-CM04S1 in immunocompromised populations, where the need for more effective vaccine options remains urgent.”
The World Vaccine Congress Europe convenes global experts across science, clinical development, manufacturing, and public health. More details can be found at World Vaccine Congress Europe.
GeoVax is also developing a vaccine targeting Mpox and smallpox, and based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. The company's oncology program includes Gedeptin®, a novel oncolytic solid tumor gene-directed therapy for advanced head and neck cancers.
For more information about GeoVax and its clinical trials, visit www.geovax.com.
